PMID- 33080301
OWN - NLM
STAT- MEDLINE
DCOM- 20210416
LR  - 20210416
IS  - 1096-0007 (Electronic)
IS  - 0014-4835 (Linking)
VI  - 202
DP  - 2021 Jan
TI  - JQ1, a selective inhibitor of BRD4, suppresses retinoblastoma cell growth by 
      inducing cell cycle arrest and apoptosis.
PG  - 108304
LID - S0014-4835(20)30562-5 [pii]
LID - 10.1016/j.exer.2020.108304 [doi]
AB  - Retinoblastoma (RB) is the most common intraocular cancer in children, and 
      chemotherapy has been the first-line treatment. However, due to the side effects 
      of chemotherapy drugs, novel treatments must be developed. JQ1, a selective 
      inhibitor of BRD4, suppresses cell growth in several cancers in which BRD4 is 
      overexpressed. In the present study, BRD4 was overexpressed in retinoblastoma, 
      and JQ1 effectively inhibited RB cell proliferation and colony formation by 
      inducing cell cycle arrest and promoting apoptosis. Furthermore, the Myc-P21-CDK2 
      and Myc-cyclinD3/CDK6 pathways were activated in RB cells treated with JQ1, and 
      an animal experiment suggested that JQ1 significantly inhibited tumour growth in 
      vivo. In conclusion, JQ1 may be a potential drug treatment for retinoblastoma.
CI  - Copyright (c) 2020. Published by Elsevier Ltd.
FAU - Zhang, Yanyan
AU  - Zhang Y
AD  - Department of Ophthalmology, The Third Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi, People's Republic of China; Jiangxi Key Laboratory 
      of Cancer Metastasis and Precision Treatment, The Third Affiliated Hospital of 
      Nanchang University, Nanchang, Jiangxi, People's Republic of China; Medical 
      Department of Graduate School, Nanchang University, Nanchang, Jiangxi, People's 
      Republic of China.
FAU - Duan, Sujuan
AU  - Duan S
AD  - Department of Ophthalmology, The Third Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi, People's Republic of China; Jiangxi Key Laboratory 
      of Cancer Metastasis and Precision Treatment, The Third Affiliated Hospital of 
      Nanchang University, Nanchang, Jiangxi, People's Republic of China.
FAU - Jang, Alan
AU  - Jang A
AD  - Jiangxi Key Laboratory of Cancer Metastasis and Precision Treatment, The Third 
      Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic 
      of China.
FAU - Mao, Longbing
AU  - Mao L
AD  - Medical Department of Graduate School, Nanchang University, Nanchang, Jiangxi, 
      People's Republic of China.
FAU - Liu, Xing
AU  - Liu X
AD  - Medical Department of Graduate School, Nanchang University, Nanchang, Jiangxi, 
      People's Republic of China.
FAU - Huang, Guofu
AU  - Huang G
AD  - Department of Ophthalmology, The Third Affiliated Hospital of Nanchang 
      University, Nanchang, Jiangxi, People's Republic of China; Jiangxi Key Laboratory 
      of Cancer Metastasis and Precision Treatment, The Third Affiliated Hospital of 
      Nanchang University, Nanchang, Jiangxi, People's Republic of China. Electronic 
      address: hgf2222@sina.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201017
PL  - England
TA  - Exp Eye Res
JT  - Experimental eye research
JID - 0370707
RN  - 0 ((+)-JQ1 compound)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Azepines)
RN  - 0 (BRD4 protein, human)
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transcription Factors)
RN  - 0 (Triazoles)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Azepines/*pharmacology
MH  - Blotting, Western
MH  - Cell Cycle/*drug effects
MH  - Cell Cycle Proteins/*antagonists & inhibitors/genetics
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival
MH  - Gene Expression Regulation, Neoplastic/physiology
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Mice
MH  - Mice, Nude
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Retinal Neoplasms/genetics/*pathology
MH  - Retinal Pigment Epithelium/drug effects
MH  - Retinoblastoma/genetics/*pathology
MH  - Signal Transduction
MH  - Transcription Factors/*antagonists & inhibitors/genetics
MH  - Triazoles/*pharmacology
OTO - NOTNLM
OT  - BRD4
OT  - JQ1
OT  - Retinoblastoma
OT  - WERI-Rb1
OT  - Y79
EDAT- 2020/10/21 06:00
MHDA- 2021/04/17 06:00
CRDT- 2020/10/20 20:07
PHST- 2019/12/15 00:00 [received]
PHST- 2020/10/02 00:00 [revised]
PHST- 2020/10/13 00:00 [accepted]
PHST- 2020/10/21 06:00 [pubmed]
PHST- 2021/04/17 06:00 [medline]
PHST- 2020/10/20 20:07 [entrez]
AID - S0014-4835(20)30562-5 [pii]
AID - 10.1016/j.exer.2020.108304 [doi]
PST - ppublish
SO  - Exp Eye Res. 2021 Jan;202:108304. doi: 10.1016/j.exer.2020.108304. Epub 2020 Oct 
      17.